Bloodstream Infections and Infective Endocarditis — Written Clinical Reasoning

Model answer — Part A: S. aureus bacteraemia on haemodialysis

Frame the problem first. This is healthcare-associated S. aureus bacteraemia with the tunneled catheter as the presumed source — a catheter-related bloodstream infection supported by the paired line and peripheral cultures — and SAB is never benign: mortality approaches one in five, and management follows its own discipline [1] [2].

Immediate assessment: sepsis severity and haemodynamic status; examination for metastatic seeding (spine, joints, epidural space — ask specifically about back pain); review for prosthetic material and devices; repeat blood cultures at 24–48 hours to document clearance, because persistent positivity declares complicated disease [1] [4].

The catheter: S. aureus is a mandatory-removal organism. Remove the tunneled catheter, establish temporary non-tunneled access for dialysis, and do not attempt salvage with lock therapy — that option exists for coagulase-negative staphylococci and selected gram-negatives, not S. aureus [2].

Antimicrobials: empirical vancomycin only until susceptibilities return; once MSSA is confirmed, switch to flucloxacillin 2 g IV 4–6 hourly (or cefazolin) because beta-lactams outperform vancomycin for MSSA bloodstream infection [5].

Echocardiography and consultation: haemodialysis dependence is a risk feature pushing toward transoesophageal echo, and an infectious diseases consult measurably improves mortality and adherence to echo and duration standards [3].

Duration reasoning: two weeks of intravenous therapy only if every uncomplicated criterion holds — source removed, no endocarditis on echo, no prosthetic material, defervescence within 72 hours, negative follow-up cultures, no metastatic foci. In a dialysis patient with catheter-related SAB, practise as four weeks unless the full uncomplicated checklist is demonstrably satisfied [1] [4].